{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:12:43Z","timestamp":1792015963376,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The optimal neoadjuvant chemotherapy (NAC) regimen for patients with localized pancreatic ductal adenocarcinoma (PDAC) remains uncertain. This trial aimed to evaluate the efficacy and safety of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), in patients with resectable\/borderline-resectable (R\/BR) PDAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>Treatment-na\u00efve patients with R\/BR-PDAC were enrolled and randomly allocated. They received two cycles (2 months) of each standard protocol, followed by radical surgery for those without tumor progression in general hospitals belonging to our intergroup. The primary endpoint was to determine the superior regimen on the basis of achieving a 10% increase in the rate of patients with progression-free survival (PFS) at 2 years from allocation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 100 patients were enrolled, with 94 patients randomly assigned to the GS arm (<jats:italic>N<\/jats:italic> = 46) or GA arm (<jats:italic>N<\/jats:italic> = 48). The 2-year PFS rates did not show the stipulated difference [GA, 31% (24\u201338%)\/GS, 26% (18\u201333%)], but the Kaplan\u2013Myer analysis showed significance (median PFS, GA\/GS 14 months\/9 months, <jats:italic>P<\/jats:italic> = 0.048; HR 0.71). Secondary endpoint comparisons yielded the following results (GA\/GS arm, <jats:italic>P<\/jats:italic>-value): rates of severe adverse events during NAC, 73%\/78%, <jats:italic>P<\/jats:italic> = 0.55; completion rates of the stipulated NAC, 92%\/83%, <jats:italic>P<\/jats:italic> = 0.71; resection rates, 85%\/72%, <jats:italic>P<\/jats:italic> = 0.10; average tumor marker (CA19-9) reduction rates, \u221250%\/\u221221%, <jats:italic>P<\/jats:italic> = 0.01; average numbers of lymph node metastasis, 1.7\/3.2, <jats:italic>P<\/jats:italic> = 0.04; and median overall survival times, 42\/22 months, <jats:italic>P<\/jats:italic> = 0.26.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study found that GA and GS are viable neoadjuvant treatment regimens in R\/BR-PDAC. Although the GA group exhibited a favorable PFS outcome, the primary endpoint was not achieved.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15199-8","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T14:01:58Z","timestamp":1711634518000},"page":"4621-4633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)"],"prefix":"10.1245","volume":"31","author":[{"given":"Daisaku","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8828-1067","authenticated-orcid":false,"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Asukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumasa","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Tsujie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osakuni","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tomokuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"issue":"9791","key":"15199_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607\u201320.","journal-title":"Lancet."},{"issue":"14","key":"15199_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473\u201381.","journal-title":"JAMA."},{"issue":"10041","key":"15199_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248\u201357.","journal-title":"Lancet."},{"issue":"1","key":"15199_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/SLA.0b013e3181ad65cc","volume":"250","author":"H Ohigashi","year":"2009","unstructured":"Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250(1):88\u201395.","journal-title":"Ann Surg."},{"issue":"124","key":"15199_CR5","first-page":"904","volume":"60","author":"H Eguchi","year":"2013","unstructured":"Eguchi H, Nagano H, Tanemura M, et al. Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Hepatogastroenterology. 2013;60(124):904\u201311.","journal-title":"Hepatogastroenterology."},{"key":"15199_CR6","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.2741\/A377","volume":"3","author":"TM Breslin","year":"1998","unstructured":"Breslin TM, Janjan NA, Lee JE, et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Front Biosci. 1998;3:E193-203.","journal-title":"Front Biosci."},{"issue":"5","key":"15199_CR7","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1245\/s10434-011-2110-8","volume":"19","author":"A Andriulli","year":"2012","unstructured":"Andriulli A, Festa V, Botteri E, et al. Neoadjuvant\/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644\u201362.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"15199_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12032-017-0951-0","volume":"34","author":"F D'Angelo","year":"2017","unstructured":"D\u2019Angelo F, Antolino L, Farcomeni A, et al. Neoadjuvant treatment in pancreatic cancer: evidence-based medicine? A systematic review and meta-analysis. Med Oncol. 2017;34(5):85.","journal-title":"Med Oncol."},{"issue":"1","key":"15199_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.23044","volume":"106","author":"KT Papalezova","year":"2012","unstructured":"Papalezova KT, Tyler DS, Blazer DG 3rd, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106(1):111\u20138.","journal-title":"J Surg Oncol."},{"issue":"8","key":"15199_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/bjs.10870","volume":"105","author":"E Versteijne","year":"2018","unstructured":"Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946\u201358.","journal-title":"Br J Surg."},{"key":"15199_CR11","unstructured":"Tempero MA, Pelzer U, O'Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. Dec 15 2022:JCO2201134."},{"issue":"2","key":"15199_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","volume":"268","author":"JY Jang","year":"2018","unstructured":"Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg. 2018;268(2):215\u201322.","journal-title":"Ann Surg."},{"issue":"16","key":"15199_CR13","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373.","journal-title":"J Clin Oncol."},{"key":"15199_CR14","doi-asserted-by":"crossref","unstructured":"Cloyd JM, Heh V, Pawlik TM, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. Apr 15 2020;9(4).","DOI":"10.3390\/jcm9041129"},{"issue":"2","key":"15199_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157\u201368.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"15199_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12957-017-1240-2","volume":"15","author":"M Dhir","year":"2017","unstructured":"Dhir M, Malhotra GK, Sohal DPS, et al. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15(1):183.","journal-title":"World J Surg Oncol."},{"key":"15199_CR17","doi-asserted-by":"crossref","unstructured":"Unno M. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05). 2019; Gastrointestinal Cancers Symposium.","DOI":"10.1200\/JCO.2019.37.4_suppl.189"},{"issue":"6","key":"15199_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","volume":"3","author":"M Reni","year":"2018","unstructured":"Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413\u201323.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"15199_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","volume":"34","author":"T Seufferlein","year":"2023","unstructured":"Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91\u2013100.","journal-title":"Ann Oncol."},{"issue":"12","key":"15199_CR20","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1245\/s10434-013-3129-9","volume":"20","author":"F Motoi","year":"2013","unstructured":"Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20(12):3794\u2013801.","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"15199_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med."},{"issue":"9","key":"15199_CR22","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.ejso.2016.01.006","volume":"42","author":"B Ielpo","year":"2016","unstructured":"Ielpo B, Duran H, Diaz E, et al. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Eur J Surg Oncol. 2016;42(9):1394\u2013400.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"15199_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s13063-021-05541-w","volume":"22","author":"D Yamada","year":"2021","unstructured":"Yamada D, Kobayashi S, Takahashi H, et al. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable\/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS\/GA-rP2, CSGO-HBP-015). Trials. 2021;22(1):568.","journal-title":"Trials."},{"key":"15199_CR24","doi-asserted-by":"crossref","unstructured":"Yamada D, Eguchi H, Asaoka T, et al. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Surg Today. Apr 18 2017.","DOI":"10.1007\/s00595-017-1522-x"},{"issue":"3","key":"15199_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/SLA.0b013e3181cc90a3","volume":"251","author":"H Takahashi","year":"2010","unstructured":"Takahashi H, Ohigashi H, Ishikawa O, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg. 2010;251(3):461\u20139.","journal-title":"Ann Surg."},{"issue":"3","key":"15199_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267\u201377.","journal-title":"JAMA."},{"issue":"10073","key":"15199_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324.","journal-title":"Lancet."},{"issue":"11","key":"15199_CR28","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8(11):1571\u20138.","journal-title":"JAMA Oncol."},{"issue":"11","key":"15199_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, Dam JLV, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220\u201330.","journal-title":"J Clin Oncol."},{"issue":"3","key":"15199_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421\u20137.","journal-title":"JAMA Oncol."},{"issue":"3","key":"15199_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9(3):205\u201317.","journal-title":"Lancet Gastroenterol Hepatol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15199-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15199-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15199-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T20:11:44Z","timestamp":1718050304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15199-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["15199"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15199-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}